X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
diabetes (7) 7
type 2 diabetes (6) 6
endocrinology & metabolism (5) 5
risk factors (5) 5
blood pressure (4) 4
cardiovascular diseases (4) 4
diabetes mellitus (4) 4
diabetes mellitus, type 2 - drug therapy (4) 4
drug administration schedule (4) 4
efficacy (4) 4
female (4) 4
glucagon-like peptides - administration & dosage (4) 4
glucagon-like peptides - adverse effects (4) 4
glucagon-like peptides - analogs & derivatives (4) 4
glycemic control (4) 4
hemoglobin (4) 4
humans (4) 4
hypoglycemic agents - administration & dosage (4) 4
hypoglycemic agents - adverse effects (4) 4
immunoglobulin fc fragments - administration & dosage (4) 4
immunoglobulin fc fragments - adverse effects (4) 4
index medicus (4) 4
male (4) 4
middle aged (4) 4
recombinant fusion proteins - administration & dosage (4) 4
recombinant fusion proteins - adverse effects (4) 4
aged (3) 3
blood glucose - drug effects (3) 3
blood glucose - metabolism (3) 3
cardiovascular disease (3) 3
cerebral infarction (3) 3
clinical trials (3) 3
diabetes mellitus, type 2 - blood (3) 3
drug dosages (3) 3
exenatide (3) 3
glucagon (3) 3
glucagon-like peptide 1 (3) 3
glucagon-like peptide-1 (3) 3
health risk assessment (3) 3
incretin (3) 3
medicine, general & internal (3) 3
myocardial infarction (3) 3
treatment outcome (3) 3
agonists (2) 2
analog liraglutide (2) 2
base-line (2) 2
biomarkers - blood (2) 2
cardiovascular diseases - diagnosis (2) 2
cardiovascular diseases - etiology (2) 2
cardiovascular diseases - mortality (2) 2
cardiovascular events (2) 2
clinical trials, phase iii as topic (2) 2
comparative analysis (2) 2
diabetes mellitus, type 2 - complications (2) 2
diabetes mellitus, type 2 - diagnosis (2) 2
diabetes mellitus, type 2 - mortality (2) 2
disease (2) 2
disease control (2) 2
drug therapy (2) 2
enzymes (2) 2
follow-up (2) 2
glucagon-like peptide-1 receptor - agonists (2) 2
glucagon-like peptide-1 receptor - metabolism (2) 2
glycosylated hemoglobin (2) 2
health risks (2) 2
hypoglycemic agents (2) 2
incidence (2) 2
kaplan-meier estimate (2) 2
kidney diseases (2) 2
liraglutide (2) 2
mellitus (2) 2
meta-analysis (2) 2
metformin (2) 2
microvasculature (2) 2
motivation (2) 2
open-label (2) 2
original investigation (2) 2
peptide-1 receptor agonists (2) 2
peptides (2) 2
proportional hazards models (2) 2
prospective studies (2) 2
protective factors (2) 2
randomization (2) 2
randomized controlled trials as topic (2) 2
risk analysis (2) 2
risk assessment (2) 2
safety (2) 2
stroke (2) 2
type-2 (2) 2
1 receptor agonist (1) 1
abridged index medicus (1) 1
american-diabetes-association (1) 1
analysis of variance (1) 1
angina (1) 1
angina pectoris (1) 1
antidiabetic drug (1) 1
appetite (1) 1
basal insulin (1) 1
blood sugar (1) 1
body weight (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cardiovascular diabetology, 02/2016, Volume 15, p. 38
Journal Article
Cardiovascular Diabetology, ISSN 1475-2840, 02/2016, Volume 15, Issue 1, pp. 38 - 38
Background: Patients with type 2 diabetes (T2D) have a substantial increased risk for cardiovascular (CV) disease and associated mortality than those without... 
Glucagon-like peptide-1 (GLP-1) | Type 2 diabetes | Cardiovascular events | Incretin | MACE | Meta-analysis | METFORMIN | GLYCEMIC CONTROL | CARDIAC & CARDIOVASCULAR SYSTEMS | EFFICACY | INTENSIVE GLUCOSE CONTROL | EXENATIDE | FOLLOW-UP | MELLITUS | PEPTIDE-1 ANALOG | RECEPTOR AGONIST DULAGLUTIDE | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | Index Medicus
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 01/2018, Volume 20, Issue 1, pp. 42 - 49
Journal Article
대한당뇨병학회 학술발표논문집, 2019, Volume 2019, p. 166
Object: Dulaglutide (DU) has demonstrated non-inferiority vs. liraglutide (LIR) and superiority vs. exenatide BID (EXE) in A1c reduction. Data on GLP-1RAs... 
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9951, pp. 1349 - 1357
Summary Background Dulaglutide and liraglutide, both glucagon-like peptide-1 (GLP-1) receptor agonists, improve glycaemic control and reduce weight in patients... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | GLYCEMIC CONTROL | EFFICACY | PHYSICAL-ACTIVITIES | SAFETY | PARALLEL-GROUP | EXENATIDE | ANALOG LIRAGLUTIDE | GATEKEEPING PROCEDURES | DAILY LIVING QUESTIONNAIRE | PEPTIDE-1 RECEPTOR AGONISTS | Metformin - therapeutic use | Glucagon-Like Peptide 1 - administration & dosage | Recombinant Fusion Proteins - adverse effects | Glucagon-Like Peptides - administration & dosage | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Male | Immunoglobulin Fc Fragments - administration & dosage | Hypoglycemic Agents - administration & dosage | Fasting - blood | Female | Glucagon-Like Peptides - analogs & derivatives | Immunoglobulin Fc Fragments - adverse effects | Recombinant Fusion Proteins - administration & dosage | Drug Administration Schedule | Glucagon-Like Peptide 1 - analogs & derivatives | Treatment Outcome | Glucagon-Like Peptides - adverse effects | Diabetes Mellitus, Type 2 - blood | Analysis of Variance | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Hypoglycemic Agents - adverse effects | Liraglutide | Type 2 diabetes | Usage | Research | Comparative analysis | Drug therapy | Clinical trials | Enzymes | Blood pressure | Diabetes | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
Diabetes Care, ISSN 0149-5992, 2014, Volume 37, Issue 8, pp. 2159 - 2167
OBJECTIVE To compare the efficacy and safety of dulaglutide, a once-weekly GLP-1 receptor agonist, with placebo and exenatide in type 2 diabetic patients. The... 
GLYCEMIC CONTROL | GLUCAGON-LIKE PEPTIDE-1 | EXENDIN-4 | SITAGLIPTIN | ENDOCRINOLOGY & METABOLISM | ANALOG LIRAGLUTIDE | OPEN-LABEL | LY2189265 | TREATED PATIENTS | Recombinant Fusion Proteins - adverse effects | Glucagon-Like Peptides - administration & dosage | Humans | Middle Aged | Male | Immunoglobulin Fc Fragments - administration & dosage | Thiazolidinediones - administration & dosage | Metformin - adverse effects | Peptides - administration & dosage | Hypoglycemic Agents - administration & dosage | Venoms - administration & dosage | Female | Metformin - administration & dosage | Drug Therapy, Combination | Glucagon-Like Peptides - analogs & derivatives | Immunoglobulin Fc Fragments - adverse effects | Recombinant Fusion Proteins - administration & dosage | Drug Administration Schedule | Venoms - adverse effects | Hypoglycemia - drug therapy | Thiazolidinediones - adverse effects | Blood Glucose - drug effects | Glucagon-Like Peptides - adverse effects | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Peptides - adverse effects | Type 2 diabetes | Care and treatment | Safety and security measures | Dosage and administration | Metformin | Comparative analysis | Exenatide | Clinical trials | Hemoglobin | Diabetes | Product safety | Drug dosages | Placebo effect | Index Medicus
Journal Article
by Gerstein, Hertzel C and Colhoun, Helen M and Dagenais, Gilles and Dagenais, Gilles R and Diaz, Rafael and Diaz, Sarahy and Lakshmanan, Mark and Pais, Prem and Probstfield, Jeffrey and Riesmeyer, Jeffrey S and Riddle, Matthew C and Rydén, Lars and Xavier, Denis and Atisso, Charles Messan and Dyal, Leanne and Hall, Stephanie and Hall, Charles and Rao-Melacini, Purnima and Wong, Gloria and Avezum, Alvaro and Basile, Jan and Chung, Ming-Min and Chung, Namsik and Chung, Jin-Wook and Conget, Ignacio and Cushman, William C and Franek, Edward and Hancu, Nicolae and Hanefeld, Christoph and Hanefeld, Markolf and Holt, Shaun and Jansky, Petr and Keltai, Matyas and Keltai, Katalin and Lanas, Fernando and Leiter, Lawrence A and Lopez-Jaramillo, Patricio and Cardona Munoz, Ernesto German and Pirags, Valdis and Pogosova, Nana and Raubenheimer, Peter J and Shaw, Jonathan E and Sheu, Wayne H-H and Temelkova-Kurktschiev, Theodora and Abella, Mercedes and Alebuena, Andrea and Almagro, Sandra and Amoroso, Eduardo and Anadon, Paula and Andreu, Elizabeth and Aristimuño, Guillermo and Arzadun, Maria and Barbieri, Maria and Barcudi, Raul and Bartolacci, Ines and Bolobanich, Gabriel and Bordonava, Anselmo and Bustamante Labarta, Miguel and Bustos, Betina and Caccavo, Alberto and Camino, Alejandra and Cantero, Maria and Carignano, Maria and Cartasegna, Luis and Cipullo, Marcela and Commendatore, Víctor and Conosciuto, Victoria and Costamagna, Osvaldo and Crespo, Claudia and Cuello, Jose and Cuneo, Carlos and Cusimano, Sandra and Dean, Sofia and Dituro, Claudio and Dominguez, Andrea and Farah, Miguel and Fernandez, Alberto and Fernandez, Florencia and Ferrari, Adriana and Flammia, Patricia and Fuentealba, Jose and Gallardo, Karina Beatriz and Garcia, Mar and Garcia, Celso and Garcia, Maria and Garcia Duran, Ruben and Garrido, Marcelo and Gavicola, Rodolfo and Gerbaudo, Claudio and Gilli, Graciela and Giotto, Ana Paula and Godoy Bolzán, Pedro and Gomez Vilamajo, Oscar and Guerlloy, Fernando and Guridi, Cristian and Gutierrez Garrido, Narcisa and Hasbani, Eduardo and Hermida, Sonia and Hominal, Miguel and Hrabar, Adrian and ... and REWIND Investigators
The Lancet, ISSN 0140-6736, 07/2019, Volume 394, Issue 10193, pp. 121 - 130
Journal Article
by Gerstein, Hertzel C and Colhoun, Helen M and Dagenais, Gilles and Dagenais, Gilles R and Diaz, Rafael and Diaz, Sarahy and Lakshmanan, Mark and Pais, Prem and Probstfield, Jeffrey and Botros, Fady T and Riddle, Matthew C and Rydén, Lars and Xavier, Denis and Atisso, Charles Messan and Dyal, Leanne and Hall, Stephanie and Hall, Charles and Rao-Melacini, Purnima and Wong, Gloria and Avezum, Alvaro and Basile, Jan and Chung, Ming-Min and Chung, Namsik and Chung, Jin-Wook and Conget, Ignacio and Cushman, William C and Franek, Edward and Hancu, Nicolae and Hanefeld, Christoph and Hanefeld, Markolf and Holt, Shaun and Jansky, Petr and Keltai, Matyas and Keltai, Katalin and Lanas, Fernando and Leiter, Lawrence A and Lopez-Jaramillo, Patricio and Cardona Munoz, Ernesto German and Pirags, Valdis and Pogosova, Nana and Raubenheimer, Peter J and Shaw, Jonathan E and Sheu, Wayne H-H and Temelkova-Kurktschiev, Theodora and Abella, Mercedes and Alebuena, Andrea and Almagro, Sandra and Amoroso, Eduardo and Anadon, Paula and Andreu, Elizabeth and Aristimuño, Guillermo and Arzadun, Maria and Barbieri, Maria and Barcudi, Raul and Bartolacci, Ines and Bolobanich, Gabriel and Bordonava, Anselmo and Bustamante Labarta, Miguel and Bustos, Betina and Caccavo, Alberto and Camino, Alejandra and Cantero, Maria and Carignano, Maria and Cartasegna, Luis and Cipullo, Marcela and Commendatore, Víctor and Conosciuto, Victoria and Costamagna, Osvaldo and Crespo, Claudia and Cuello, Jose and Cuneo, Carlos and Cusimano, Sandra and Dean, Sofia and Dituro, Claudio and Dominguez, Andrea and Farah, Miguel and Fernandez, Alberto and Fernandez, Florencia and Ferrari, Adriana and Flammia, Patricia and Fuentealba, Jose and Gallardo, Karina Beatriz and Garcia, Mar and Garcia, Celso and Garcia, Maria and Garcia Duran, Ruben and Garrido, Marcelo and Gavicola, Rodolfo and Gerbaudo, Claudio and Gilli, Graciela and Giotto, Ana Paula and Godoy Bolzán, Pedro and Gomez Vilamajo, Oscar and Guerlloy, Fernando and Guridi, Cristian and Gutierrez Garrido, Narcisa and Hasbani, Eduardo and Hermida, Sonia and Hominal, Miguel and Hrabar, Adrian and ... and REWIND Investigators
The Lancet, ISSN 0140-6736, 07/2019, Volume 394, Issue 10193, pp. 131 - 138
Journal Article